8 detection of bacterial antigens and alzheimer’s disease-like pathology in the central nervous system of balb/c mice following intranasal infection with a laboratory isolate of chlamydia pneumoniae

9 multi-target screening and experimental validation of natural products from selaginella plants against alzheimer's disease

10 traditional used plants against cognitive decline and alzheimer disease

11 the cellular prion protein: a player in immunological quiescence

12 the effects of fatty acids of nigella sativa seeds on apoptosis and oxidative stress induced by doxorubicin in pc12 cell line as a neuronal model

13 heterogeneidade cognitiva na doença de alzheimer cognitive heterogeneity in alzheimer's disease

14 additional mechanisms conferring genetic susceptibility to alzheimer's disease

15 el rol de la evaluaciÓn neuropsicolÓgica en el diagnÓstico y en el seguimiento de las demencias

16 alzheimer´s disease: a clinical-practice-oriented review

17 differential processing of natural scenes in typical and atypical alzheimer disease measured with a saccade choice task

18 Measurement of CSF α‐synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer’s disease

19 La enfermedad de Alzheimer: importante desafío sociosanitario para el médico de familia

20 Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

21 Cholinesterase inhibitors for Alzheimer's disease

22 Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease.

23 Alzheimer's disease against peptides products of enzymatic cleavage APP protein: Biological, pathobiological and physico-chemical properties of fibrillating peptides

24 Cholinesterase inhibitors as Alzheimer's therapeutics (Review).

25 Use of Cholinesterase Inhibitors in Non-Alzheimer's Dementias.

26 Reconsideration of anticholinesterase therapeutic strategies against alzheimer's disease

27 Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease.

28 Synthesis and biological evaluation of flavone-8-acrylamide derivatives as potential multi-target-directed anti Alzheimer agents and investigation of binding mechanism with acetylcholinesterase.

29 Discovery of N-methylpiperazinyl flavones as a novel class of compounds with therapeutic potential against Alzheimer's disease: Synthesis, binding affinity towards amyloid β oligomers (Aβo) and ability to disrupt Aβo-PrP <sup>C</sup> interactions

30 Protection of cholinergic and antioxidant system contributes to the effect of Vitamin D<inf>3</inf> ameliorating memory dysfunction in sporadic dementia of Alzheimer's type

31 Investigation of the Effects of Biochemical Parameters on Alzheimer's Disease.

32 Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships

33 Biomarkers for Alzheimer’s Disease in Saliva: A Systematic Review

34 Immunosenescence of Natural Killer Cells, Inflammation, and Alzheimer’s Disease

35 Impaired Cerebral Vasomotor Reactivity in Alzheimer’s Disease

36 Alzheimer’s Disease Mortality according to Socioeconomic Factors: Country Study

37 Alzheimer’s Disease Frontal Cortex Mitochondria Show a Loss of Individual Respiratory Proteins but Preservation of Respiratory Supercomplexes

38 Development of Regional Disparities in Alzheimer’s Disease Mortality in the Slovak Republic from 1996 to 2015

39 Physician Practice Patterns Associated with Diagnostic Evaluation of Patients with Suspected Mild Cognitive Impairment and Alzheimer’s Disease

40 Longitudinal brain atrophy patterns and neuropsychological performance in older adults with HIV-associated neurocognitive disorder compared with early Alzheimer's disease.

41 The Model of Aging Acceleration Network Reveals the Correlation of Alzheimer's Disease and Aging at System Level.

42 Early Alzheimer's disease-type pathology in the frontal cortex of wild mountain gorillas (Gorilla beringei beringei).

43 Fecal metabolite of a gnotobiotic mouse transplanted with gut microbiota from a patient with Alzheimer's disease.

44 Visual perceptual disorders in Alzheimer's disease.

45 Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.

46 Meta-Analysis of Gene Expression and Identification of Biological Regulatory Mechanisms in Alzheimer's Disease.

47 Corrigendum to “Fuzzy adaptive cognitive stimulation therapy generation for Alzheimer's sufferers: Towards a pervasive dementia care monitoring platform” (Future Generation Computer Systems (2018) 88 (479–490), (S0167739X1830089X) (10.1016/j.future.2018.06.018))

48 Promoter Polymorphism-219T/G is an Effect Modifier of the Influence of ε4 on Alzheimer's Disease Risk in a Multiracial Sample.

49 Advance of sporadic Alzheimer's disease animal models.

50 Evaluation of the Music Engagement Program for people with Alzheimer's disease and dementia: Study protocol for a pilot trial.

51 Plasma Neurofilament Light Chain Levels Are Associated With Cortical Hypometabolism in Alzheimer Disease Signature Regions.

52 Molecular Inverse Comorbidity between Alzheimer's Disease and Lung Cancer: New Insights from Matrix Factorization.

53 [Alzheimer's disease and related disorders: specificity of young onset patients, including ethical aspects].

54 Vitamin D concentration and risk of Alzheimer disease: A meta-analysis of prospective cohort studies.

55 The "rights" of precision drug development for Alzheimer's disease.

56 Probiotic treatment improves the impaired spatial cognitive performance and restores synaptic plasticity in an animal model of Alzheimer's disease.

57 Current State of Digital Biomarker Technologies for Real-Life, Home-Based Monitoring of Cognitive Function for Mild Cognitive Impairment to Mild Alzheimer Disease and Implications for Clinical Care: Systematic Review.

58 Synthesis, biological evaluation, and molecular modeling of nitrile-containing compounds: Exploring multiple activities as anti-Alzheimer agents.

59 Radiosynthesis of carbon-11 labeled PDE5 inhibitors as new potential PET radiotracers for imaging of Alzheimer's disease.

60 Dynamic structural determinants underlie the neurotoxicity of the N-terminal tau 26-44 peptide in Alzheimer's disease and other human tauopathies.

61 White matter alterations in early-stage Alzheimer's disease: A tract-specific study.

62 Risk estimation before progression to mild cognitive impairment and Alzheimer's disease: an AD resemblance atrophy index.

63 Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease.

64 Is Low Psychomotor Speed a Marker of Brain Vulnerability in Late Life? Digit Symbol Substitution Test in the Prediction of Alzheimer, Parkinson, Stroke, Disability, and Depression.

65 Prediction of Alzheimer's disease based on deep neural network by integrating gene expression and DNA methylation dataset

66 Investigation of Cerebral Hemodynamic Changes in Mild Cognitive Impairment Due to Alzheimer’s Disease During a Verbal Fluency Task

67 Automatic detection of alzheimer disease based on histogram and random forest

68 Dysfunction of the ubiquitin ligase E3A Ube3A/E6-AP contributes to synaptic pathology in Alzheimer’s disease

69 Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model

70 Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model

71 Alzheimer's disease-like pathology-triggered oxidative stress, alterations in monoamines levels, and structural damage of locus coeruleus neurons are partially recovered by a mix of proteoglycans of embryonic genesis

72 Visualizing Alzheimer’s Disease Mouse Brain with Multispectral Optoacoustic Tomography using a Fluorescent probe, CDnir7

73 Synaptic and memory dysfunction in a β-amyloid model of early Alzheimer's disease depends on increased formation of ATP-derived extracellular adenosine

74 Possible epigenetic regulatory effect of dysregulated circular RNAs in Alzheimer’s disease model

75 Blockade of α4 integrins reduces leukocyte–endothelial interactions in cerebral vessels and improves memory in a mouse model of Alzheimer’s disease

76 Serum and brain natural copper stable isotopes in a mouse model of Alzheimer’s disease

77 Defective autophagy and Alzheimer's disease: Is calcium the key?

78 Differentiating between Alzheimer's disease, amnestic mild cognitive impairment, and normal aging via diffusion kurtosis imaging

79 Optogenetics-induced activation of glutamate receptors improves memory function in mice with Alzheimer's disease

80 Glucocorticoid receptors modulate dendritic spine plasticity and microglia activity in an animal model of Alzheimer's disease

81 Fecal microbiota transplantation alleviated Alzheimer’s disease-like pathogenesis in APP/PS1 transgenic mice

82 Regional mitochondrial DNA and cell-type changes in post-mortem brains of non-diabetic Alzheimer’s disease are not present in diabetic Alzheimer’s disease

83 Reversibility of Age-related Oxidized Free NADH Redox States in Alzheimer’s Disease Neurons by Imposed External Cys/CySS Redox Shifts

84 The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in in vitro and in vivo models of Alzheimer's disease

85 Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model

86 Acute restraint stress reverses impaired LTP in the hippocampal CA1 region in mouse models of Alzheimer’s disease

87 Screening older adults for amnestic mild cognitive impairment and early-stage Alzheimer’s disease using upper-extremity dual-tasking

88 Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer’s disease

89 Electroencephalography reveals lower regional blood perfusion and atrophy of the temporoparietal network associated with memory deficits and hippocampal volume reduction in mild cognitive impairment due to Alzheimer’s disease

90 A comment on effect of plant extracts on Alzheimer′s disease: An insight into therapeutic avenues

91 Legal medical consideration of Alzheimer’s disease patients’ dysgraphia and cognitive dysfunction a 6 month follow up

92 Evaluation of Gene-Based Family-Based Methods to Detect Novel Genes Associated With Familial Late Onset Alzheimer Disease

93 Are TallyHo Mice A True Mouse Model for Type 2 Diabetes and Alzheimer's Disease?

94 Somatic mutation that affects transcription factor binding upstream of CD55 in the temporal cortex of a late-onset Alzheimer disease patient.

95 Commentary: Donepezil enhances understanding of degraded speech in Alzheimer's disease

96 CBIR system using Capsule Networks and 3D CNN for Alzheimer's disease diagnosis

97 Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid.

98 Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.

99 Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases.

100 Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches

101 Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging.

Keyword Connections

Journals

Research Groups

Bibliographies